Glycostem today announced that the first patient has been dosed in its pivotal phase I/IIa trial of oNKord® for the treatment of Acute Myeloid Leukemia (AML). The WiNK trial will enroll 33 AML patients at eight clinical sites based in five European countries. oNKord® is the company’s first-generation off-the-shelf allogeneic NK cellular immunotherapy product. Glycostem is furthermore developing a range of second (CAR-NK) and third generation (TCR-NK) NK products in-house.